High-performance liquid chromatographic determination of chlordiazepoxide and major related impurities in pharmaceuticals.
A rapid, precise, forward-phase (adsorption) high-performance liquid chromatographic procedure is presented for the determination of chlordiazepoxide and two common impurities, 7-chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one 4-oxide and 2-amino-5-chlorobenzophenone, in commercial formulations and for the determination of the benzophenone in the chlordiazepoxide drug substance. The method involves simultaneous quantitation of chlordiazepoxide and the 1,3-dihhydro impurity, followed by quantitation of the benzophenone from a separate sample extract using a second mobile phase. A single microparticulate silica gel column is used throughout. Nitrazepam and o-dinitrobenzene are the internal standards, Quantitation is by peak area using a computing integrator, except that the peak due to the benzophenone is quantitated by peak height. The described procedure is of equivalent precision, but superior accuracy, to the BP 1973 spectrophotometric procedure for the analysis of chlordiazepoxide in chlordiazepoxide formulations. Quantitation of the 1,3-dihydro and the benzophenone impurities at levels as low as 6.3 and 0.9 ng, respectively, is demonstrated.
D001570:Benzodiazepinones / Q000032:analysis*; D001577:Benzophenones / Q000032:analysis*; D002214:Capsules / Q000032:analysis; D002707:Chlordiazepoxide / Q000032:analysis*; D002851:Chromatography, High Pressure Liquid; D004340:Drug Contamination; D008722:Methods; D013607:Tablets / Q000032:analysis
D001570:Benzodiazepinones; D001577:Benzophenones; D002214:Capsules; D013607:Tablets; D002707:Chlordiazepoxide; C014317:2-amino-5-chlorobenzophenone